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Background: Aleglitazar is a dual peroxisome proliferator-activated receptor _/a agonist in development for cardiovascular risk reduction in 
patients following an acute coronary syndrome (ACS) who have type 2 diabetes mellitus. Most ACS patients receive aspirin, which is associated with 
decreased glomerular filtration rate (GFR). Aleglitazar has been shown to cause a dose-dependent decrease in GFR that is reversible with treatment 
cessation and likely attributable to intrarenal hemodynamic effects. This study determined the effect of aleglitazar in combination with low-dose 
aspirin on renal function.
Methods: In this randomized, double-blind, placebo-controlled study, healthy volunteers (n=44) aged 40-65 years with normal renal function 
were randomized to receive aleglitazar (150 μg qd) or placebo for 4 weeks, followed by 1 week of aspirin (325 mg qd) in addition to randomized 
treatment. Measured GFR (mGFR, measured as iohexol clearance), effective renal plasma flow (ERPF, measured as para-amino hippuric acid 
clearance) and platelet aggregation were assessed prior to treatment, and at end of Weeks 4 and 5.
Results: Thirty-nine subjects completed the study. Following co-administration of aleglitazar and aspirin, changes in mGFR and ERPF did not differ 
from changes after administration of placebo and aspirin, comparing Week 5 to Week 4 (placebo-corrected change 0% [90% CI -5.4 to 5.7] and 
-1.4% [90% CI -8.9 to 6.7], respectively). Aleglitazar alone did not result in a notable mGFR decrease from baseline (placebo-corrected change 
-1.4% [90% CI -5.5 to 2.8]) nor a change in ERPF (placebo-corrected change 3.5% [90% CI -1.7 to 8.9]). Aspirin alone resulted in an mGFR change 
of -4.4% (90% CI -7.9 to -0.7) and an ERPF change of -5.8% (90% CI -10.8 to -0.5) from baseline. The antiplatelet effect of aspirin was unaffected 
by co-administration of aleglitazar and the pharmacokinetics of aleglitazar were unaffected by aspirin. Adverse events were similar between groups, 
and mostly mild in severity.
Conclusion: Co-administration of aleglitazar and aspirin did not change the effect size of alterations in renal function induced by low-dose aspirin 
and did not affect the antiplatelet function of aspirin.
